The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of disposable vitreous injection of FT-003 in subjects with Diabetic Macular Edema (DME). The study was divided into two phases, Phase 1 dose escalation and Phase II dose expansion.
Eligibility
Sex
ALL
Min age
18 Years
Max age
74 Years
Healthy volunteers
No
Inclusion Criteria:
* Subjects that are willing and able to follow study procedures;
* Female or male patients 18-74 years old at the time of signing the ICF;
* Clinically diagnosed with CI-DME;
* The best corrected visual acuity (BCVA) of the studied eye is 24-73 letters;
Exclusion Criteria:
* Presence of any other intraocular diseases other than DME in the studied eye that would affect the improvement of visual acuity and require treatment during the study for prevention or treatment of visual loss, as judged by the investigator.
Primary outcome measure(s)
Safety and tolerability after FT-003 injection — At Week 12 Incidence and severity of AE (Common Terminology Criteria for Adverse Events 5.0)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.